Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 7;12(9):2535.
doi: 10.3390/cancers12092535.

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug

Günter Emons  1 , Alexander Mustea  2 , Clemens Tempfer  3
Affiliations
Review

Tamoxifen and Endometrial Cancer: A Janus-Headed Drug

Günter Emons et al. Cancers (Basel). .

Abstract

Tamoxifen is a selective estrogen receptor modulator used for the treatment and prevention of estrogen receptor (ER)-positive breast cancer. However, tamoxifen increases the risk of endometrial cancer (EC) by about 2-7 fold, and more aggressive types of EC with poor prognoses are observed in tamoxifen users. On the other hand, tamoxifen is an efficacious treatment for advanced or recurrent EC with low toxicity. The differential agonistic or antagonistic effects of tamoxifen on ERα are explained by the tissue-specific expression profiles of co-activators and co-repressors of the receptor. The estrogen-agonistic effect of tamoxifen in endometrial cancers can also be explained by the expression of G-protein coupled estrogen receptor 1 (GPER-1), a membrane-bound estrogen receptor for which tamoxifen and other "antiestrogens" are pure agonists.

Keywords: endometrial cancer; selective estrogen receptor modulator; tamoxifen.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jordan V.C. The 38th David A. Karnofsky lecture: The paradoxical actions of estrogen in breast cancer—Survival or death? J. Clin. Oncol. 2008;26:3073–3082. doi: 10.1200/JCO.2008.17.5190. - DOI - PubMed
    1. Jordan V.C. The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture. Ann. Surg. Oncol. 2019;26:1981–1990. doi: 10.1245/s10434-019-07291-1. - DOI - PMC - PubMed
    1. Potkul R.K., Unger J.M., Livingston R.B., Crew K.D., Wilczynski S.P., Salomon C.G., Smith B.L., Wong L., Campbell D.L., Einspahr D.E., et al. Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630. NPJ Breast Cancer. 2016;2:16024. doi: 10.1038/npjbcancer.2016.24. - DOI - PMC - PubMed
    1. Killackey M.A., Hakes T.B., Pierce V.K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep. 1985;69:237–238. - PubMed
    1. Fleming C.A., Heneghan H.M., O’Brien D., McCartan D.P., McDermott E.W., Prichard R.S. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br. J. Surg. 2018;105:1098–1106. doi: 10.1002/bjs.10899. - DOI - PubMed

LinkOut - more resources